1. Retrospective Correction of ADC for Gradient Nonlinearity Errors in Multicenter Breast DWI Trials: ACRIN6698 Multiplatform Feasibility Study
- Author
-
Malyarenko, Dariya I, Newitt, David C, Amouzandeh, Ghoncheh, Wilmes, Lisa J, Tan, Ek T, Marinelli, Luca, Devaraj, Ajit, Peeters, Johannes M, Giri, Shivraman, Endt, Axel Vom, Hylton, Nola M, Partridge, Savannah C, and Chenevert, Thomas L
- Subjects
Medical and Biological Physics ,Biomedical and Clinical Sciences ,Clinical Sciences ,Physical Sciences ,Oncology and Carcinogenesis ,Clinical Trials and Supportive Activities ,Breast Cancer ,Biomedical Imaging ,Clinical Research ,Cancer ,Breast ,Breast Neoplasms ,Diffusion Magnetic Resonance Imaging ,Feasibility Studies ,Female ,Humans ,Nonlinear Dynamics ,Reproducibility of Results ,Retrospective Studies ,Nonuniform diffusion weighting ,gradient nonlinearity bias ,retrospective correction ,multi-platform clinical trials ,breast cancer therapy response ,apparent diffusion coefficient - Abstract
The presented analysis of multisite, multiplatform clinical oncology trial data sought to enhance quantitative utility of the apparent diffusion coefficient (ADC) metric, derived from diffusion-weighted magnetic resonance imaging, by reducing technical interplatform variability owing to systematic gradient nonlinearity (GNL). This study tested the feasibility and effectiveness of a retrospective GNL correction (GNC) implementation for quantitative quality control phantom data, as well as in a representative subset of 60 subjects from the ACRIN 6698 breast cancer therapy response trial who were scanned on 6 different gradient systems. The GNL ADC correction based on a previously developed formalism was applied to trace-DWI using system-specific gradient-channel fields derived from vendor-provided spherical harmonic tables. For quantitative DWI phantom images acquired in typical breast imaging positions, the GNC improved interplatform accuracy from a median of 6% down to 0.5% and reproducibility of 11% down to 2.5%. Across studied trial subjects, GNC increased low ADC (
- Published
- 2020